The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls. (HealthDay News) — Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an ...

WEDNESDAY, April 30, 2025 (HealthDay News) -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study ...

To evaluate the relative benefits and harms of therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose co-transporter-2 inhibitors (SGLT2i), and their combination in adults ...

Sodium transporters maintain cellular homeostasis by transporting ions, minerals, and nutrients across the membrane, and Na+/K+ ATPases facilitate the cotransport of solutes ... such as sodium-glucose ...

To achieve maximum sensitivity of the search strategy and identify all randomized control trials, we combined sodium‐glucose cotransport‐2, SGLT2 inhibitor, canagliflozin, dapagliflozin, empagliflozin ...

ABSTRACT: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a promising class of medications for type 2 diabetes mellitus (DM2) treatment. This study aims to evaluate the clinical efficacy, ...

About The Study: In this study of discharge prescription of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) among patients hospitalized for heart failure, prescription rates increased ...

Abu-Hammour MN, et al. Association of sodium glucose co-transporter-2 inhibitors and serious liver events in patients with cirrhosis on diuretics: A global cohort study. Presented at: ACG Annual ...

Sodium-glucose cotransport 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may be among the most important advances in decades for patients with kidney disease.